{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-26-000009","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.895698+00:00","generated_at":"2026-05-15T23:40:43.550206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada posts Q4 net loss of $39.2M; cash at $295.7M; DMD program advances","bullets":["Net loss of $39.2M in Q4 2025 vs net income of $1.1M in Q4 2024; full-year net loss of $143.8M.","Cash, cash equivalents and marketable securities of $295.7M as of Dec 31, 2025; runway into Q3 2027.","DMC recommended initiating Cohort 2 of ELEVATE-44-201 at 12 mg/kg; Cohort 1 data expected Q2 2026.","ELEVATE-45-201 Cohort 1 data on track for mid-2026; ENTR-601-50 regulatory authorization in UK obtained.","Nomination of ENTR-801 for Usher syndrome type 2A; second ocular candidate expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-26-000009","json":"https://secwatch.observer/filing/0001689375-26-000009.json","markdown":"https://secwatch.observer/filing/0001689375-26-000009.md","text":"https://secwatch.observer/filing/0001689375-26-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000009/0001689375-26-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000009/trda-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:40:43.550206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}